Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Intuit Inc. (INTU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Intuit Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Intuit Inc. trades at $277 (market cap $75.21B). The key difference: Intuit Inc. is the larger of the two by market cap, and Intuit Inc. pays a 1.75% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | INTU | |
|---|---|---|
Market Cap | $39.89B | $75.21B |
Sector | Health | Technology |
52-Week High | $491.22 | $807.39 |
52-Week Low | $278.09 | $255.07 |
Enterprise Value | $38.15B | $73.67B |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Intuit (INTU) trades at $274.96, up 0.58% on the day, with a neutral technical signal and strong fundamentals. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $12.8 exceeding expectations. Revenue grew to $18.83B in 2025, and net income margin expanded to 20.54%. However, the stock faces headwinds from multiple law firm investigations into securities fraud allegations related to TurboTax pricing, contributing to a significant stock drop over the past year.
The outlook is mixed: strong financial performance and a consensus price target of $433.69 suggest upside potential, but legal risks and bearish technical indicators warrant caution. Investment opportunities lie in Intuit's AI-driven growth and market leadership, while risks include ongoing litigation and competitive pressures in the fintech space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →
